Back

Two-year effectiveness and safety outcomes in 27,333 edoxaban-treated patients with and without a history of major bleeding from the Global ETNA-AF programme

26 August 2022 (08:00 - 19:30)
Organised by:
Congress Presentation Part of: How to balance efficacy and safety of anticoagulant therapy in clinical practice Anticoagulants ESC Professional Premium Access ESC Congress 2022

About the speaker

Photo
Professor Raffaele De Caterina

University of Pisa, Pisa (Italy)

7 More presentations in this session

Presentation thumbnail
Reduced dose, but not reduced risk: rates of inappropriate apixaban dose reduction and stroke and bleeding incidence
Doctor J. Harrington (Boulder, US)
Abstract Slides
Presentation thumbnail
D-dimer-driven versus standard prophylactic anticoagulation with fondaparinux in critically ill patients with COVID-19 and coagulopathy: an open-label, randomized controlled trial
Doctor L. Adrian (Surabaya, ID)
Abstract Slides
Presentation thumbnail
Real-world effectiveness and safety of edoxaban in patients with and without a history of ischaemic stroke: results from the ETNA-AF programme
Professor R. De Caterina (Pisa, IT)
Abstract Slides
Presentation thumbnail
Performance assessment of unfractionated heparin protocol in pediatric patients supported on extracorporeal membrane oxygenation
Ms E. Shorog (Riyadh, SA)
Abstract Slides
Presentation thumbnail
Protective effect of proton pump inhibitor against gastrointestinal bleeding in patients receiving oral anticoagulants: A systematic review and meta-analysis
Doctor H. Ahn (Seoul, KR)
Abstract Slides

Access the full session

Session thumbnail
How to balance efficacy and safety of anticoagulant therapy in clinical practice

The Event

Event poster

ESC Congress 2022

26 August - 29 August 2022
You may be interested in
thumbnail
Congress Presentation
State-of-the-art lecture on pharmacotherapy for acute coronary syndromes
thumbnail
Webinar
Antithrombotic treatment for dual pathway inhibition in cardiovascular disease patients
thumbnail
Congress Presentation
Direct oral anticoagulants or warfarin in patients with left ventricular thrombus: a meta-analysis of randomized clinical trials

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources